<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2BD4D4F3-7D93-41A3-844F-83DFC280D7BC"><gtr:id>2BD4D4F3-7D93-41A3-844F-83DFC280D7BC</gtr:id><gtr:name>Mgb Biopharma Limited</gtr:name><gtr:address><gtr:line1>151 WEST GEORGE STREET</gtr:line1><gtr:city>GLASGOW</gtr:city><gtr:postCode>G2 2JJ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2BD4D4F3-7D93-41A3-844F-83DFC280D7BC" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>2BD4D4F3-7D93-41A3-844F-83DFC280D7BC</gtr:id><gtr:name>Mgb Biopharma Limited</gtr:name><gtr:address><gtr:line1>151 WEST GEORGE STREET</gtr:line1><gtr:city>GLASGOW</gtr:city><gtr:postCode>G2 2JJ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>1319669.0</gtr:offerGrant><gtr:projectCost>2199449.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B1DFE13B-8B40-4434-A868-FC0B8569D6EE"><gtr:id>B1DFE13B-8B40-4434-A868-FC0B8569D6EE</gtr:id><gtr:firstName>Dawn</gtr:firstName><gtr:surname>Firmin</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=101877"><gtr:id>11AB25B3-DEA6-4EFC-ABD4-35A5ECA4A9A8</gtr:id><gtr:title>Phase I study to assess tolerability, safety and PK of MGB-BP-3 in healthy volunteers</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>101877</gtr:grantReference><gtr:abstractText>MGB Biopharma is developing a new class of antibiotic originally discovered in the UK by researchers at the University of Strathclyde. The drug,MGB-BP-3, has a novel mechanism of action which means that resistant bacteria will not be a feature as is the case with existing antibiotics. The first indication to be developed is the treatment of Clostridium difficile infections and the Techology Strategy Board has provided grant funding to complete the human safety study. This drug, and potentially others from the same platform, shows promise for further development for the treatment of other infections, including MRSA and other serious life threatening infections against which existing drugs are becoming less effective due to the increase in resistant bacteria.</gtr:abstractText><gtr:fund><gtr:end>2016-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1319669</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">101877</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>